Serotonin dysfunction disorders: A behavioral neurochemistry perspective

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 8, 1996, Pages 11-16

  Petty, Frederick ^a   Davis, Lori L ^b   Kabel, David ^b   Kramer, Gerald L ^b  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; DOPAMINE; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; IMIPRAMINE; NEUROTRANSMITTER; NORADRENALIN; RESERPINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

ANXIETY; HELPLESSNESS; HUMAN; MENTAL DISEASE; MICRODIALYSIS; MOOD; NERVE CELL NETWORK; NEUROCHEMISTRY; NEUROTRANSMISSION; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM; THINKING;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; COGNITION DISORDERS; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; DOPAMINE; GAMMA-AMINOBUTYRIC ACID; HELPLESSNESS, LEARNED; HUMANS; NOREPINEPHRINE; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN; SEROTONIN AGENTS; SEROTONIN UPTAKE INHIBITORS;

EID: 0029787284     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Harris TH. Depression induced by rauwolfia compounds. Am J Psychiatry 1957;113:950-963
2. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965;122:509-522
3. Bunney WE Jr, Davis JM. Norepinephrine in depressive reactions: a review. Arch Gen Psychiatry 1965;13:483-494
4. Coppen A. The biochemistry of affective disorders. Br J Psychiatry 1967; 113:1237-1264
5. Coppen AJ, Shaw DM, Farrell JP. Potentiation of the antidepressant effect of a monoamine oxidase inhibitor by tryptophan. Lancet 1963;1:79-81
6. Woolley DW, Shaw E. Some neurophysiological effects of serotonin [letter]. BMJ 1954;2:122
7. Cooper JR, Bloom FE, Roth RH. The Biochemical Basis of Neuropharmacology. 6th ed. Oxford, England: Oxford University Press; 1991
8. Walker RJ. The pharmacology of serotonin receptors in invertebrates. In: Green AR, ed. Neuropharmacology of Serotonin. Oxford, England: Oxford University Press; 1985:366-408
9. Glass JD, Hauser UE, Blank JL, et al. Differential timing of amino acid and 5-HIAA rhythms in suprachiasmatic hypothalamus. Am J Physiol 1993; 265(2):R504-R511
10. Bowers MB. The role of drags in the production of schizophreniform psychoses and related disorders. In: Meltzer HY, ed. Psychopharmacology: The Third Generation in Progress. New York, NY: Raven Press; 1987:819-823
11. Coppen AJ, Shaw DM, Herzberg B. Tryptophan in the treatment of depression. Lancet 1967;2:1178-1180
12. van Praag HM, Korf J, Dols LCW, et al. A pilot study of the predictive value of the probenecid test in the application of 5-hydroxytryptophan as an antidepressant. Psychopharmacologia 1972;25:14-21
13. Asberg M, Thoren P, Traskman L. "Serotonin depression": a biochemical subgroup within the affective disorders? Science 1975;191:478-480
14. Brown G, Goodwin FG, Ballenger J, et al. Aggression in humans correlates with cerebrospinal fluid amine metabolites. Psychiatry Res 1979;1:131-139
15. Coccaro EF, Siever LJ, Klar HM, et al. Serotonergic studies in patients with affective and personality disorders: correlates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry 1989;46:587-599
16. Delgado PL, Price LH, Miller HM, et al. Rapid serotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and neurobiology of depression. Psychopharmacol Bull 1991;27:321-330
17. Maser JD, Cloninger CR. Comorbidity of Mood and Anxiety Disorders. Washington, DC: American Psychiatric Press; 1990
18. Rutter JJ, Gundlah C, Auerbach SB. Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine. Neurosci Lett 1994;171:183-186
19. Fuller RW. Minireview: uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. Life Sci 1994;55:163-167
20. Bel N, Artigas F. Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse 1993;15: 243-245
21. Griebel G, Moreau JL, Jenck F, et al. Acute and chronic treatment with S-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents. Psychopharmacology (Berl) 1994;113:463-470
22. Jordan S, Kramer GL, Zukas PK, et al. In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine, and fluvoxamine. Synapse 1994;18:294-297
23. Petty F, Kramer G, Wilson L. Prevention of learned helplessness: in vivo correlation with cortical serotonin. Pharmacol Biochem Behav 1992;43: 361-367
24. Wilde MI, Benfield P. Tianeptine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and co-existing anxiety and depression. Drugs 1995;49:411-439